Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018
April 24 2018 - 4:05PM
Business Wire
-Conference Call Scheduled for Tuesday, May 8,
2018 at 4:30pm ET-
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the Company will
release first quarter 2018 financial results on Tuesday, May 8,
2018 after the close of market. Revance will host a corresponding
conference call and a live webcast at 1:30pm PT/4:30pm ET on the
same day to discuss the results and provide a business and pipeline
update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers and reference conference ID:
4580549; or from the webcast link in the investor relations section
of the company’s website at: www.revance.com.
A replay of the call will be available beginning May 8, 2018 at
4:30pm PT/7:30pm ET to May 9, 2018 at 4:30pm PT/7:30pm ET. To
access the replay, dial (855) 859-2056 or (404) 537-3406 and
reference conference ID: 4580549. The webcast will be available in
the investor relations section on the company’s website for 30 days
following the completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and
pain. The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis, with
plans to initiate studies in upper limb spasticity and chronic
migraine. RT002 has the potential to be the first long-acting
neuromodulator. Revance has developed a proprietary, stabilizing
excipient peptide technology designed to create novel,
differentiated therapies. The company has a comprehensive pipeline
based upon its peptide technology, including injectable and topical
formulations of daxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180424006055/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino,
917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024